Reata Pharmaceuticals. has filed a patent for C4 modified oleanolic acid derivatives and analogs. The patent also covers pharmaceutical compositions, manufacturing methods, and the use of these compounds for preventing and treating diseases associated with overproduction of IL-17. GlobalData’s report on Reata Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Reata Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Reata Pharmaceuticals, NSAID cancer drugs was a key innovation area identified from patents. Reata Pharmaceuticals's grant share as of September 2023 was 78%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230250130A1) describes a compound of interest and its various forms and applications. The compound is represented by a specific chemical formula. The patent claims provide detailed information about the compound and its variations.

The compound, as described in claim 1, is further defined in subsequent claims. These definitions include the presence of specific functional groups and substituents. The patent also mentions the compound's potential use in pharmaceutical compositions.

The patent claims highlight the compound's versatility and potential applications. For example, claim 48 specifies that the compound can have different variations of R2, which is a specific chemical group. These variations include hydroxy, acyl, alkoxy, acyloxy, and alkylsilyloxy groups, among others. The claims also mention the possible values for m and n, which determine the length and composition of R2.

Furthermore, claim 61 introduces an alternative form of R2, represented by R5'?. This form can have different functional groups, such as alkoxy, acyloxy, substituted acyloxy, alkylsilyloxy, or substituted alkylsilyloxy. The claim also specifies the possible values for m2, which determine the length of R2 in this alternative form.

The patent also includes claims related to the compound's pharmaceutical applications. Claim 144 describes a pharmaceutical composition comprising the compound of claim 1 and an excipient or a pharmaceutically acceptable carrier. This composition can be used for various therapeutic purposes.

Additionally, claim 146 outlines a method of treating or preventing a disease or disorder in a patient by administering a therapeutically effective amount of the compound of claim 1. This claim suggests that the compound may have potential therapeutic benefits.

Overall, the patent provides detailed information about a compound and its various forms, as well as its potential applications in pharmaceutical compositions and therapeutic treatments. The claims offer a comprehensive understanding of the compound's structure and potential uses, making it an interesting development in the field.

To know more about GlobalData’s detailed insights on Reata Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies